Obinutuzumab Bests Rituximab in Previously Untreated Follicular Lymphoma
Obinutuzumab plus chemotherapy improved progression-free survival and time to next treatment.
Diagnosis & Disease Information
Kymriah Gets Accelerated Approval for Relapsed/Refractory Follicular Lymphoma
The accelerated approval for Kymriah was based on data from the phase 2 ELARA trial.
GALEN Combination Yields Promising Results in Untreated Follicular Lymphoma
Researchers sought to determine whether the GALEN regimen would yield favorable clinical outcomes in patients with previously untreated follicular lymphoma.
Mosunetuzumab Effective for Patients With Follicular Lymphoma After at Least 2 Prior Lines of Therapy
Researchers sought to determine whether mosunetuzumab would be effective for treating relapsed/refractory FL in patients with 2 or more prior lines of therapy.
Postinduction Therapy Based on Response for Patients With Follicular Lymphoma
Researchers sought to determine whether patients with FL would have different PFS with postinduction therapy using a response-adapted approach.
Novartis Receives Priority Review by FDA for Tisagenlecleucel in Relapsed or Refractory Follicular Lymphoma
The FDA granted a priority review for tisagenlecleucel in the treatment of adult patients with relapsed or refractory follicular lymphoma after 2 prior lines of treatment.
Shorter Obinutuzumab Infusions May Be Safe, Effective in Follicular Lymphoma
Researchers sought for approval in Europe for obinutuzumab to be administered for a shorter, 90-minute infusion time among patients with previously untreated or previously treated follicular lymphoma.
Bone Marrow and Extracellular Vesicles Associated With Development of Follicular Lymphoma B Cells
Researchers sought to determine whether there is a role for extracellular vesicles associated with follicular lymphoma B cells in the alteration of bone marrow stroma.
Baseline SUVmax May Have Prognostic Value in Patients With Follicular Lymphoma
Researchers sought to determine whether baseline SUVmax would have prognostic value in patients with follicular lymphoma.
Intratumoral T-Cells Affect FDG-PET Prognostic Efficacy in Follicular Lymphoma
Researchers sought to determine how chemoimmunotherapies can affect FDG-PET parameters and influence interpretation of results in patients with FL.
- Loading...
Loading...
Loading... 
Loading...